After bleomycin instillation, acute lung inflammation developed (day 7), and at this stage, we observed no change of α-SMA expression compared with the control group, but the expression of α-SMA increased on days 14 and 21, which were significantly alleviated by treatment with mDASCs. The gene discussed is ACTA1; the disease is inflammation.